Health In Tech, Inc. director Hayes Timothy sold 12,000 shares at $0.89 each. The transaction matters to investors because it represented about 9.9% of his prior holding in Health In Tech, leaving him with 108,780 shares after the sale.
Key Highlights
- The transaction was dated September 14.
- Transaction code S identifies the deal as an open-market sale.
- Hayes Timothy held 108,780 shares after the transaction.
Health In Tech, Inc. (NASDAQ: HIT) director Hayes Timothy sold 12,000 shares at $0.89 per share.
September 14 Open-Market Sale
The transaction took place on September 14. Transaction code S identifies it as an open-market sale.
Sale Equaled About 9.9% of
Prior Holding The transaction represented about 9.9% of Hayes Timothy’s prior shareholding. His recorded position after the sale was 108,780 shares. The percentage compares the shares sold with his holding before the transaction. The 108,780 figure represents his ownership after the transaction.
FAQs
Q: How many Health In Tech shares did Hayes Timothy sell?
A: Hayes Timothy sold 12,000 Health In Tech shares in the transaction. The filing reported a sale price of $0.89 per share.
Q: What was the Health In Tech insider transaction code?
A: The filing lists transaction code S for the sale. In the filing’s transaction classification, code S identifies an open-market sale.
Q: How many shares did Hayes Timothy own after the sale?
A: Hayes Timothy held 108,780 Health In Tech shares after the transaction. He is identified as a director of the company.
Q: What percentage of Hayes Timothy’s prior holding did the sale represent?
A: The transaction represented about 9.9% of Hayes Timothy’s prior shareholding. The percentage relates the shares sold to his holding before the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.